The company operates an online professional physician platform in China. As of December 31, 2022, the company's platform had approximately 2.9 million registered physician users, and the company's average monthly active users reached about 2.7 million in 2022. The company's Metz Medicine platform also has a high percentage of senior physician users with the title of Deputy Chief Physician and above. According to the latest data published by the National Health and Health Commission, the total number of registered physician users with the title of deputy chief physician and above on the company's Mace Medical platform accounted for 67.1% of the total number of physicians with the title of deputy chief physician and above in China. The Metz Medical Platform can be accessed through various channels such as the website, mobile app, WeChat Mini Program, and WeChat account. The company mainly provides customers with physician platform solutions, accurate omni-channel marketing solutions and RWS solutions. The company believes the solutions can help generate and share meaningful medical evidence with a wider community of physicians and help guide physicians' prescribing decisions to promote the rational use of medical products and add value and better care to patients. The company is committed to strengthening its position as a platform-based, professional-oriented digital medical technology company, and hopes to improve the overall quality of care for patients using the value provided by generating and sharing medical evidence.

The company's total revenue increased from 216 million yuan in 2020 to 349 million yuan in 2022. Due to changes in the fair value of convertible bonds and preferred shares, the company's net profit in 2022 lost about 100 million yuan. The market capitalization of the company after listing was about 6 billion Hong Kong dollars. The prospectus price corresponds to 2022 PS about 17 times. If the valuation is higher, it is recommended to purchase carefully.